Table 2.

Summary of the effects of intravenous immunoglobulin (IVIG) treatment upon components of both innate and acquired immunity.

Innate Immunity Component	Effect of IVIG on component
Natural Killer (NK) cells	- Increased activation - Increased cytokine production and degranulation - Increased anti-tumor effect - Migration from blood to tissue
Dendritic cells (DCs)	- Decreased endocytosis - Decreased pro-inflammatory cytokine production - Increased anti-inflammatory cytokine production - Decreased differentiation - Increased NK cell-mediated ADCC - Decreased expression of MHC class II and co-stimulatory molecules - Decreased DC-mediated T cell activation - Decreased expression of activating FcγR - Increased expression of CD1d
Macrophages	- Increased production of IL-1Ra - Decreased activation - Decreased production of pro-inflammatory cytokines - Decreased expression of IFN-γR2 - Decreased expression of activating FcγR - Blockade of activating FcγR - Increased expression of inhibitory FcγRIIB
Neutrophils	- Decreased activation due to IgG monomers inhibiting FcγR - Increased activation by IgG dimers binding FcγR or by ANCA - Decreased adhesion to endothelium - Increased death by Siglec
Acquired Immunity Component	Effect of IVIG on component
T cells	- Increased apoptosis - Decreased IL-2 production - Decreased differentiation - Decreased activation and proliferation
Treg cells	- Increased production - Increased suppressive action
B cells	- Increased apoptosis - Decreased proliferation - Regulation of antibody production - Increase in inhibitory FcγRIIB - Neutralization of survival factors - Inhibition of activating FcγR